Image credit: WuXi Biologics
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, which will become part of the company's CRDMO hub in Singapore. Under a strategic collaboration between WuXi Biologics and Pharmadule Morimatsu, 470 modular components are being fabricated at Morimatsu's plant in Changshu City, and will be transported to Singapore's Tuas Biomedical Park for installation. Once complete, the building will be one of the world's largest modular biologics DP facilities, comprising approximately 30,000 square meters of space.
The new facility will feature state-of-the-art manufacturing lines, centralized Quality Control (QC) labs supporting full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, significantly enhancing the company's end-to-end DP services capabilities. Equipped with three pre-filled syringe (PFS) production lines and two vial production lines for both liquid and lyophilized products, it will deliver integrated DP manufacturing services — across both clinical and commercial stages — for multiple finished dosage forms. As part of WuXi Biologics' commitment to sustainability, the facility will incorporate green technologies such as solar panels, and an advanced energy monitoring and analysis system. Operations are expected to commence in 2027.
In addition, the design phase is underway for a Drug Substance (DS) modular facility planned for the Singapore CRDMO hub.
As a key contributor to the global healthcare industry, WuXi Biologics provides end-to-end solutions and services for its clients through an extensive global network, including 5 Research Centers, 8 Development Centers and 8 Manufacturing Centers (with 9 DP facilities and 16 DS facilities in operation). The company's state-of-the-art DP manufacturing facilities provide formulation, filling, labelling, and packaging of biotherapeutics, vaccines, placebo and parenterals that are filled into either liquid, lyophilized, or PFS dosage forms.
With facilities in Ireland, Germany, the United States, Singapore, and China, and a total planned capacity exceeding 500,000L, WuXi Biologics offers clients access to a reliable and premier-quality global network. Through its Global Dual Sourcing strategy, the company ensures that materials can be sourced and products manufactured at multiple locations around the world, enhancing supply chain reliability and operational flexibility.
